What if the very strategies intended to reduce harm from drug use are actually endangering the very people they aim to protect? This episode of the Drug Report promises to tackle the complexities and controversies surrounding research into harm reduction in drug policy. With significant federal funding now backing harm reduction research, we stress the critical importance of reputable science in shaping effective policies. Hear our nuanced critique on the growing influence of drug normalization in policy-making, through revealing case studies like the Greater Harlem Coalition's experience with pro-drug Yale researchers.
But that’s not all. We dive into the murky waters of ethical concerns surrounding drug research, spotlighting the scandal involving Lykos (formerly MAPS) and its contentious clinical trials for psychedelic drugs. The Wall Street Journal's reports on unreported suicidal ideation among trial subjects raise alarming questions about participant safety and research ethics, echoing historical parallels with the tobacco industry. Finally, don't miss out on our exciting announcement about the TDR newsletter, brimming with insightful articles and a compelling editorial piece. Your feedback is invaluable to us, and we hope you find this episode as thought-provoking as we do.
Follow the work of SAM and FDPS below:
https://learnaboutsam.org/
https://gooddrugpolicy.org/
https://thedrugreport.org/
On X:
https://twitter.com/learnaboutsam
https://twitter.com/GoodDrugPolicy
https://twitter.com/KevinSabet
https://twitter.com/LukeNiforatos
On Facebook: https://www.facebook.com/learnaboutsam
